Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13382807 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL14586400 | 1.00 | CASP3 (0.54) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL12138344 | 0.91 | CASP3 (0.58) | CASP3KMT2AMDM4TP53MDM2 | |
| SCHEMBL14559793 | 0.91 | CASP3 (0.58) | CASP3KMT2AMDM4TP53MDM2 | |
| SCHEMBL5385200 | 0.91 | CASP3 (0.58) | CASP3KMT2AMDM4TP53MDM2 | |
| SCHEMBL13382806 | 0.91 | CASP3 (0.61) | CASP3KMT2AMDM4TP53MDM2 | |
| SCHEMBL7163160 | 0.91 | CASP3 (0.61) | CASP3KMT2AMDM4TP53MDM2 | |
| SCHEMBL26258624 | 0.90 | CASP3 (0.52) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL10028351 | 0.90 | KMT2A (0.53) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL13863441 | 0.90 | KMT2A (0.53) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8303956-B2 | Glycosylated specificity exchangers | CHRONTECH PHARMA AB (SE) | 2012-11-06 | — | — | US | disclosed |
| US-20100183635-A1 | GLYCOSYLATED SPECIFICITY EXCHANGERS | TRIPEP AB (SE) | 2010-07-22 | — | — | US | disclosed |
| US-20090305949-A1 | GLYCOSYLATED SPECIFICITY EXCHANGER | TRIPEP AB (SE) | 2009-12-10 | — | — | US | disclosed |
| US-7534435-B2 | Glycosylated specificity exchangers | TRIPEP AB (SE) | 2009-05-19 | — | — | US | disclosed |
| US-20090092631-A1 | GLYCOSYLATED SPECIFICITY EXCHANGERS THAT INDUCE AN ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) RESPONSE | TRIPEP AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-7332166-B2 | Glycosylated specificity exchangers | TRIPEP AB (SE) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090305949-A1 | GLYCOSYLATED SPECIFICITY EXCHANGER | SLC17A5, ASGR1, SLC2A1 | CASP3 4880/4885KMT2A 3283/4885MDM4 4771/4885 |
| US-20090092631-A1 | GLYCOSYLATED SPECIFICITY EXCHANGERS THAT INDUCE AN ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) RESPONSE | SLC17A5, ASGR1, FCGR1A | CASP3 4179/4885KMT2A 3756/4885MDM4 4458/4885 |
| US-20100183635-A1 | GLYCOSYLATED SPECIFICITY EXCHANGERS | SLC17A5, ASGR1, SLC2A1 | CASP3 4878/4885KMT2A 3462/4885MDM4 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.